Survivin anti-apoptotic effect

Figure 3.8 Effect of combination of down-regulation of two anti-apoptotic genes (survivin and bcl-2) and cisplatin treatment. The dose regimen was designed based on the pilot studies (doses dl-dl4) (a). Mice bearing A549°° tumours were treated with nine different combinations as described (five mice per treatment group) for over 2 weeks and the tumour growth and other safety measurements were monitored. Comparison of the antitumour efficacy of cisplatin treated mice with survivin+cisplatin treated mice, cisplatin treated mice with bcl-2+cisplatin treated mice, cisplatin treated mice with CTL siRNA+cisplatin treated mice, cisplatin treated mice with survivin+cisplatin and survivin+bcl-2+cisplatin treated mice (b). Adapted from S. Ganesh, A.K. Iyer, J. Weiler, D.V. Morrissey and M.M. Amiji, Molecular Therapy-Nucleic Acids, 2013, 2, ellO [23]...

---